Infectious disease test kit ODZ-398

IgGIgMBorrelia burgdorferi

Lyme borreliosis (LB) is a serious disease in which there is a risk of developing systemic diseases, autoimmune reactions and post-infectious disease. The causative agents are strains of the genus Borrelia. The vector of transmission is all developmental stages of the tick Ixodes. In Europe, it is a common tick (Ixodes ricicnus). The infection occurs mainly 36 hours after the tick bite. The disease is divided into several stages into early localized, disseminated and late disseminated. There are only about 10% of chronic forms in the late stage. The primary feature is a localized skin lesion, erythema migrans (50% of cases). Clinical manifestations depend in part on the type of borrelia, as each tends to migrate to other tissues. Lyme arthritis is the most common in B. burgdorferi sensu stricto (71%), neuroborreliosis in B. garinii (22%) and cutaneous manifestations in B. afzelii (5%). ELISA-VIDITEST anti-Borrelia recombinant IgG + VlsE (CSF) - immunonenzymatic ELISA kit for quantitative and semi-quantitative detection of IgG class antibodies against antigens of major pathogenic borrelia strains (B. afzelii, B. garinii and B. burgdorferi sensu stricto) in human serum, plasma, cerebrospinal fluid The determination of antibodies specific against antigens of human pathogenic strains of Borrelia is one of the tools used in the diagnosis of Lyme borreliosis (LB). Accurate test for the detection of antibodies using ELISA principles available to all laboratory service providers. Test type: Solid-phase immunoanalytical test - break-away strips in the handling frame Type of evaluation: Quantitative, Semi-quantitative